XTL Biopharmaceuticals Ltd. (XTLB)Healthcare | Biotechnology | Herzliya, Israel | NasdaqCM
1.98 USD
+0.03
(1.533%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:39 a.m. EDT
The immediate outlook is bearish due to a precarious balance sheet and deteriorating fundamentals. The company sits at a current ratio of 0.395, indicating severe liquidity stress, while free cash flow is deeply negative. This financial fragility is compounded by recent news of a subsidiary insolvency and a Nasdaq delisting warning, which suggests the business model is under existential threat rather than just cyclical pressure. Although the stock recently spiked on volume, this appears to be a speculative reaction to a potential turnaround or acquisition rumor rather than a sustainable trend, especially given the massive gap between the current price and the 200-day moving average. There is no dividend to provide income, and the lack of earnings makes any valuation attempt highly speculative. For a long-term holder, the trajectory is catastrophic: the stock has lost nearly 70% of its value over the last nine years, with the most recent annual performance showing another significant decline. The combination of insolvency risks, delisting threats, and a multi-year downward trend renders this a clear avoid. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.074518 |
| AutoETS | 0.074585 |
| MSTL | 0.076630 |
| AutoTheta | 0.109208 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 34.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.408 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,865,531 |
| Beta | 0.43 |
| Website | https://www.xtlbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6335878 |
| Address1 | 85 Medinat Hayehudim St. |
| All Time High | 2,400.0 |
| All Time Low | 1.92 |
| Ask | 2.27 |
| Ask Size | 10 |
| Average Daily Volume10 Day | 14,140 |
| Average Daily Volume3 Month | 8,443 |
| Average Volume | 8,443 |
| Average Volume10Days | 14,140 |
| Beta | 0.425 |
| Bid | 1.66 |
| Bid Size | 2 |
| Book Value | -0.0 |
| City | Herzliya |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.9799 |
| Current Ratio | 0.395 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.9799 |
| Day Low | 1.92 |
| Display Name | XTL Biopharmaceuticals |
| Dividend Date | 1,486,684,800 |
| Dividend Yield | 0.0 |
| Ebitda | -1,266,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.783 |
| Enterprise Value | 4,789,532 |
| Eps Trailing Twelve Months | -0.36 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.4966 |
| Fifty Day Average Change | -0.5166999 |
| Fifty Day Average Change Percent | -0.20696144 |
| Fifty Two Week Change Percent | -63.358776 |
| Fifty Two Week High | 6.24 |
| Fifty Two Week High Change | -4.2601 |
| Fifty Two Week High Change Percent | -0.6827083 |
| Fifty Two Week Low | 1.92 |
| Fifty Two Week Low Change | 0.059900045 |
| Fifty Two Week Low Change Percent | 0.03119794 |
| Fifty Two Week Range | 1.92 - 6.24 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,125,581,400,000 |
| Float Shares | 1,748,461 |
| Free Cashflow | -2,116,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 1.9799 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21441 |
| Held Percent Institutions | 0.00265 |
| Implied Shares Outstanding | 2,457,463 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,774,396,800 |
| Last Split Factor | 1:4 |
| Long Business Summary | XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel. |
| Long Name | XTL Biopharmaceuticals Ltd. |
| Market | us_market |
| Market Cap | 4,865,531 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_36775 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -759,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,869,055 |
| Open | 1.926 |
| Operating Cashflow | -1,025,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.27 |
| Phone | 972 5 4228 8897 |
| Previous Close | 1.95 |
| Price Hint | 4 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.181 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.029899955 |
| Regular Market Change Percent | 1.5333309 |
| Regular Market Day High | 1.9799 |
| Regular Market Day Low | 1.92 |
| Regular Market Day Range | 1.92 - 1.9799 |
| Regular Market Open | 1.926 |
| Regular Market Previous Close | 1.95 |
| Regular Market Price | 1.9799 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 4,287 |
| Return On Assets | -0.2101 |
| Return On Equity | -0.29299 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,457,463 |
| Shares Percent Shares Out | 0.0025 |
| Shares Short | 6,050 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 11,229 |
| Short Name | XTL Biopharmaceuticals Ltd. |
| Short Percent Of Float | 0.0033000002 |
| Short Ratio | 1.13 |
| Source Interval | 15 |
| Symbol | XTLB |
| Total Cash | 76,000 |
| Total Cash Per Share | 0.031 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.7763 |
| Two Hundred Day Average Change | -0.79639995 |
| Two Hundred Day Average Change Percent | -0.2868566 |
| Type Disp | Equity |
| Volume | 4,287 |
| Website | https://www.xtlbio.com |
| Zip | 4,676,670 |